Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response

NCT04082260 is registered in ClinicalTrials.gov with University Hospital Muenster as lead sponsor.

NCT NCT04082260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04082260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response
Lead sponsor
University Hospital Muenster
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2017
Completion date
January 31, 2022
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis